Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$3.62 -0.5%	$4.85	$3.50 ▼ $8.14	$866.10M	0.76	4.38 million shs	5.44 million shs
CADL Candel Therapeutics	$4.80 +0.8%	$6.04	$3.79 ▼ $14.60	$236.50M	-0.92	1.47 million shs	450,729 shs
COLL Collegium Pharmaceutical	$28.89 +5.9%	$28.10	$23.23 ▼ $42.29	$928.29M	0.63	436,387 shs	561,658 shs
ZYME Zymeworks	$11.31 -0.1%	$11.86	$8.21 ▼ $17.70	$786.92M	1.24	605,349 shs	658,545 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-0.69%	-12.35%	-19.56%	-35.13%	-57.31%
CADL Candel Therapeutics	+0.73%	-9.09%	-5.70%	-44.57%	-55.68%
COLL Collegium Pharmaceutical	+5.94%	+4.48%	+9.56%	-6.26%	-24.09%
ZYME Zymeworks	-0.09%	-12.73%	+13.10%	-20.80%	+24.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.5078 of 5 stars	4.5	2.0	4.4	2.4	2.5	0.6
CADL Candel Therapeutics	2.2411 of 5 stars	3.5	1.0	0.0	2.8	2.5	0.6
COLL Collegium Pharmaceutical	3.9675 of 5 stars	3.4	1.0	3.0	2.6	0.8	2.5
ZYME Zymeworks	2.4632 of 5 stars	3.4	0.0	0.0	3.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	2.90	Moderate Buy	$10.39	186.99% Upside
CADL Candel Therapeutics	3.00	Buy	$21.00	337.50% Upside
COLL Collegium Pharmaceutical	2.80	Moderate Buy	$43.80	51.61% Upside
ZYME Zymeworks	2.88	Moderate Buy	$21.00	85.68% Upside

Current Analyst Ratings Breakdown

Latest CADL, ZYME, COLL, and ARDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/2/2025	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/2/2025	ARDX Ardelyx	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$11.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
4/9/2025	COLL Collegium Pharmaceutical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
3/24/2025	COLL Collegium Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/14/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/12/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
3/11/2025	ZYME Zymeworks	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00
3/10/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $13.00
3/7/2025	ARDX Ardelyx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$15.00

(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$361.71M	2.39	N/A	N/A	$0.73 per share	4.96
CADL Candel Therapeutics	$120K	1,970.80	N/A	N/A	$0.44 per share	10.91
COLL Collegium Pharmaceutical	$631.45M	1.47	$10.47 per share	2.76	$5.99 per share	4.82
ZYME Zymeworks	$76.30M	10.31	N/A	N/A	$6.63 per share	1.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.22	N/A	11.68	N/A	-11.73%	-24.87%	-10.51%	N/A
CADL Candel Therapeutics	-$37.94M	-$1.75	N/A	N/A	N/A	N/A	-629.29%	-173.39%	5/13/2025 (Estimated)
COLL Collegium Pharmaceutical	$48.15M	$1.86	12.45	4.80	N/A	14.78%	104.67%	18.38%	N/A
ZYME Zymeworks	-$118.67M	-$1.61	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	N/A

Latest CADL, ZYME, COLL, and ARDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	N/A	N/A	N/A	N/A	N/A
5/8/2025	N/A	ZYME Zymeworks	-$0.45	-$0.30	+$0.15	N/A	$20.65 million	$27.11 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million
3/13/2025	Q4 2024	CADL Candel Therapeutics	-$0.23	-$0.40	-$0.17	-$0.40	N/A	N/A
2/27/2025	Q4 2024	COLL Collegium Pharmaceutical	$1.54	$1.63	+$0.09	$0.36	$179.68 million	$181.95 million
2/20/2025	Q4 2024	ARDX Ardelyx	$0.02	$0.02	N/A	$0.02	$111.16 million	$116.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	0.87	4.58	4.31
CADL Candel Therapeutics	N/A	1.18	1.18
COLL Collegium Pharmaceutical	3.43	0.97	0.88
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
CADL Candel Therapeutics	13.93%
COLL Collegium Pharmaceutical	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	5.90%
CADL Candel Therapeutics	41.60%
COLL Collegium Pharmaceutical	2.51%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	239.26 million	222.88 million	Optionable
CADL Candel Therapeutics	60	49.27 million	18.97 million	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	30.97 million	Optionable
ZYME Zymeworks	460	69.58 million	67.56 million	Optionable

CADL, ZYME, COLL, and ARDX Headlines

Recent News About These Companies

Zymeworks May 2025 slides: Pipeline expansion amid modest revenue growth

May 10 at 6:42 PM | investing.com

Zymeworks Inc. Reports Financial Results and Highlights Recent Developments, Including Appointment of Dr. Sabeen Mekan and AACR Poster Presentations

May 10 at 6:42 PM | nasdaq.com

Zymeworks Inc. (NYSE:ZYME) Q1 2025 Earnings Call Transcript

May 10 at 6:42 PM | msn.com

Zymeworks Inc. (NYSE:ZYME) Shares Bought by Voya Investment Management LLC

May 10 at 4:10 AM | marketbeat.com

Zymeworks Inc.: Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 10 at 12:10 AM | finanznachrichten.de

Zymeworks outlines robust pipeline advancements and financial resilience through 2027

May 10 at 12:10 AM | msn.com

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 10 at 12:10 AM | finance.yahoo.com

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

May 9 at 12:09 AM | seekingalpha.com

Zymeworks Inc. 2025 Q1 - Results - Earnings Call Presentation

May 8 at 10:58 PM | seekingalpha.com

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

May 8 at 6:56 PM | zacks.com

Blackstone Inc. Has $8.34 Million Stock Position in Zymeworks Inc. (NYSE:ZYME)

May 8 at 6:09 AM | marketbeat.com

Raymond James Financial Inc. Takes $888,000 Position in Zymeworks Inc. (NYSE:ZYME)

May 8 at 3:27 AM | marketbeat.com

Jazz Pharmaceuticals Stock Price, Quotes and Forecasts

May 7 at 5:37 PM | benzinga.com

Zymeworks Inc. (NYSE:ZYME) Shares Sold by BVF Inc. IL

May 6, 2025 | marketbeat.com

Zymeworks (ZYME) Projected to Post Earnings on Thursday

May 6, 2025 | americanbankingnews.com

Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus PT from Brokerages

May 5, 2025 | americanbankingnews.com

Acuta Capital Partners LLC Acquires Shares of 67,240 Zymeworks Inc. (NYSE:ZYME)

May 4, 2025 | marketbeat.com

Invesco Ltd. Reduces Position in Zymeworks Inc. (NYSE:ZYME)

May 4, 2025 | marketbeat.com

Zymeworks Inc. (NYSE:ZYME) Given Consensus Recommendation of "Moderate Buy" by Analysts

May 4, 2025 | marketbeat.com

Q2 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

May 3, 2025 | marketbeat.com

Susquehanna Fundamental Investments LLC Purchases New Shares in Zymeworks Inc. (NYSE:ZYME)

May 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
3 Stocks Presenting Generational Buying Opportunities
By Chris Markoch | April 25, 2025
View 3 Stocks Presenting Generational Buying Opportunities
Hims & Hers Stock Soars on Novo Nordisk Collaboration
By Gabriel Osorio-Mazilli | April 30, 2025
View Hims & Hers Stock Soars on Novo Nordisk Collaboration

CADL, ZYME, COLL, and ARDX Company Descriptions

Ardelyx NASDAQ:ARDX

$3.62 -0.02 (-0.55%)

As of 05/9/2025 04:00 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Candel Therapeutics NASDAQ:CADL

$4.80 +0.04 (+0.84%)

As of 05/9/2025 03:58 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Collegium Pharmaceutical NASDAQ:COLL

$28.89 +1.62 (+5.94%)

As of 05/9/2025 03:51 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Zymeworks NYSE:ZYME

$11.31 -0.01 (-0.09%)

As of 05/9/2025 04:00 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time